Nora G. Singer
A5006738078- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Adolescent and Pediatric Healthcare
- Renal Diseases and Glomerulopathies
- Long-Term Effects of COVID-19
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Cell Adhesion Molecules Research
- Atherosclerosis and Cardiovascular Diseases
- Osteoarthritis Treatment and Mechanisms
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Inflammasome and immune disorders
- Lipid metabolism and disorders
- Mesenchymal stem cell research
- Kawasaki Disease and Coronary Complications
- Immunodeficiency and Autoimmune Disorders
- Vasculitis and related conditions
- Musculoskeletal Disorders and Rehabilitation
- Gout, Hyperuricemia, Uric Acid
- Bone fractures and treatments
MetroHealth Medical Center
2016-2025
Case Western Reserve University
2015-2025
University School
2000-2025
University Hospitals of Cleveland
2004-2025
MetroHealth
2012-2025
Duke University
2024
Singer (United States)
2004-2023
University of Alabama at Birmingham
2022
Alberta Children's Hospital
2021
University of Calgary
2021
We observed a syndrome of intermittent fevers, early-onset lacunar strokes and other neurovascular manifestations, livedoid rash, hepatosplenomegaly, systemic vasculopathy in three unrelated patients. suspected genetic cause because the disorder presented early childhood.We performed whole-exome sequencing initial patients their unaffected parents candidate-gene with similar phenotype, as well two young siblings polyarteritis nodosa one patient small-vessel vasculitis. Enzyme assays,...
As in previous years, the consensus group to consider use of biological agents treatment rheumatic diseases met during 13th Annual Workshop on Advances Targeted Therapies April, 2011. The consisted rheumatologists from a number universities among continents Europe, North America, South Australia and Asia. Pharmaceutical industry support was obtained companies for annual workshop itself, but these had no part decisions about specific programme or academic participants at this conference....
Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated corticosteroids (CS) mycophenolate mofetil (MMF).This was randomized, double-blind, placebo-controlled Phase II/III, 52-week study. At screening (Day -14), high-dose CS...
Introduction Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may trigger autoimmune disease (AD) through initial innate immune activation with subsequent aberrations in adaptive cells leading to AD. While there are multiple reports of incident AD diagnosed after COVID-19, the risk context key circulating strains is unknown. Methods TriNetX, a global, federated, health research network providing access electronic medical records across 74 healthcare organizations, was utilized...
Importance A substantial number of individuals worldwide experience long COVID, or post-COVID condition. Other postviral and autoimmune conditions have a female predominance, but whether the same is true for especially within different subgroups, uncertain. Objective To evaluate sex differences in risk developing COVID among adults with SARS-CoV-2 infection. Design, Setting, Participants This cohort study used data from National Institutes Health (NIH) Researching to Enhance Recovery...
Abstract Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may occur after infection. How often people develop ME/CFS SARS-CoV-2 infection is unknown. Objective To determine the incidence and prevalence of post-COVID-19 among adults enrolled in Researching COVID to Enhance Recovery (RECOVER-Adult) study. Design, Setting, Participants RECOVER-Adult a longitudinal observational cohort study conducted across U.S. We included participants who had visit at least 6 months no...
Abstract Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able slow structural damage remain elusive. This study was undertaken evaluate effect glucosamine chondroitin sulfate (CS), alone or in combination, as well celecoxib placebo on progressive loss joint space width (JSW) patients with OA. Methods A 24‐month, double‐blind, placebo‐controlled study, conducted at 9 sites United States part...
Knee osteoarthritis (OA) is a major cause of pain and functional limitation in older adults, yet longer-term studies medical treatment OA are limited.
This study was undertaken to evaluate the long-term safety and effectiveness of etanercept alone or in combination with methotrexate (MTX) children selected categories juvenile idiopathic arthritis (JIA).Patients ages 2-18 years rheumatoid factor (RF)-positive RF-negative polyarthritis, systemic JIA, extended oligoarthritis were eligible for study. Patients received MTX (> =10 mg/m(2)/week [ approximately 0.3 mg/kg/week], maximum dosage 1 mg/kg/week), (0.8 mg/kg/week, dose 50 mg), plus 3 an...
To formulate consensus treatment plans (CTPs) for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in juvenile systemic erythematosus (SLE).A structured formation process was employed by the members Childhood Arthritis and Rheumatology Research Alliance after considering existing medical evidence current approaches.After an initial Delphi survey (response rate = 70%), a 2-day conference, 2 followup surveys rates 63-79%), achieved limited set CTPs addressing LN. These...
Abstract Objective To compare the criteria for Wegener's granulomatosis (WG) of American College Rheumatology (ACR) with those European League Against Rheumatism/Pediatric Society (EULAR/PRES) in a cohort children WG and other antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAVs), to describe interval diagnosis, presenting features, initial treatment WG. Methods Eligible patients had been diagnosed by site rheumatologists (termed “MD diagnosis”) since 2004. This diagnosis...
Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy safety children adolescents with systemic lupus erythematosus (SLE) are unknown. This study was undertaken to determine 3-year of atorvastatin preventing subclinical progression pediatric-onset SLE.
Objective To assess the efficacy and safety of rilonacept, an interleukin‐1 inhibitor, in a randomized, double‐blind, placebo‐controlled trial. Methods An initial 4‐week double‐blind placebo phase was incorporated into 24‐week randomized multicenter design, followed by open‐label phase. Seventy‐one children who had active arthritis ≥2 joints were (1:1) to 2 arms study. Patients rilonacept arm received (loading dose 4.4 mg/kg 2.2 weekly, subcutaneously) beginning on day 0. for 4 weeks loading...
To evaluate risk factors for subclinical atherosclerosis in a population of patients with pediatric systemic lupus erythematosus (SLE).In prospective multicenter study, cohort 221 underwent baseline measurements carotid intima-media thickness (CIMT) as part the Atherosclerosis Prevention Pediatric Lupus Erythematosus (APPLE) trial. SLE disease measures, medications, and traditional were assessed. A standardized protocol was used to assess bilateral common arteries mean maximal IMT 12...
Abstract Objective To determine whether neutrophil gelatinase–associated lipocalin (NGAL) can predict worsening of global and renal disease activity in childhood‐onset systemic lupus erythematosus (SLE). Methods One hundred eleven patients with SLE were enrolled a longitudinal, prospective study quarterly visits had at least 3 visits. At each visit, was measured using external standards: the numerically converted British Isles Lupus Assessment Group (BILAG) index, Disease Activity Index 2000...
Importance SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms other health effects after the acute phase of infection; termed post-acute sequelae (PASC), long COVID. The characteristics, prevalence, trajectory and mechanisms PASC are ill-defined. objectives Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study Adults (RECOVER-Adult) to: (1) characterize prevalence; (2) symptoms, organ dysfunction, natural history, distinct phenotypes PASC; (3)...
There are currently no validated clinical biomarkers of postacute sequelae SARS-CoV-2 infection (PASC).
Significance Multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, is driven by activated T lymphocytes invade brain and spinal cord, leading to damage myelin sheaths surround nerve axons. Current treatments are only partly successful, especially for later stages of chronic forms MS. Experimental encephalomyelitis (EAE) a useful animal model MS, suitable testing new approaches treatment. By genetically altering mice eliminate lymphocyte surface protein known...
It has been proposed that CD6, an important regulator of T cells, functions by interacting with its currently identified ligand, CD166, but studies performed during the treatment autoimmune conditions suggest CD6-CD166 interaction might not account for CD6 in diseases. The antigen recognized mAb 3A11 as a new ligand distinct from yet identity it is hitherto unknown. We have this CD318, cell surface protein previously found to be present on various epithelial cells and many tumor cells. that,...
Objective Participants in the Atherosclerosis Prevention Paediatric Lupus Erythematosus (APPLE) trial were randomised to placebo or atorvastatin for 36 months. The primary endpoint, reduced carotid intima medial thickness (CIMT) progression, was not met but atorvastatin-treated participants showed a trend of slower CIMT progression. Post-hoc analyses performed assess subgroup benefit from therapy. Methods Subgroups prespecified and defined by age (> ≤15.5 years), systemic lupus...